INTRODUCTION
cancer, Lung cancer, death
LUNG CANCER, CANCER, LUNG CANCER
Lung cancer has been the most common cancer in the world for several decades, accounting for 11.6% of the total new cases in 2018, and was also the leading cause of cancer‐related death (18.4% of the total cancer deaths).Four to six cycles of platinum‐based chemotherapy have been the standard care for patients with ES‐SCLC for the past 25 years.Anti‐angiogenesis agents are important treatment strategy in non‐small cell lung cancer when initiated as first‐line or maintenance treatment.Anlotinib (AL3818) is a new orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet‐derived growth factor receptors (PDGFR) and c‐kit.Both preclinical and clinical trials have suggested that antiangiogenic therapy has the potential to alleviate immunosuppression via inhibiting Treg differentiation and promoting the maturation of dendritic cells, thus showing synergetic effect.